Angiotensin-(1-7): A new therapeutic strategy in the management of atrial fibrillation

International Journal of Cardiology

Volumn 147, Issue 2, 2011, Pages 287-288

  Li, Yang ^a   Li, Guangping ^a   Liu, Tong ^a  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Angiotensin II; Angiotensin (1 7); Atrial fibrillation; Atrial remodeling; Renin angiotensin system

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN[1-7]; ATENOLOL; DIPEPTIDYL CARBOXYPEPTIDASE; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLACEBO; TRANDOLAPRIL; TRANSCRIPTION FACTOR;

ACUTE HEART INFARCTION; CARDIOVERSION; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE REFRACTORY PERIOD; HEART PROTECTION; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LETTER; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 79951950168     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.12.040     Document Type: Article

References (26)

1. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 2002;415:219-26. (Pubitemid 34059528)
2. Tsang TS, Miyasaka Y, Barnes ME, Gersh BJ. Epidemiological profile of atrial fibrillation: a contemporary perspective. Prog Cardiovasc Dis 2005;48:1-8. (Pubitemid 41368554)
3. Shiroshita-Takeshita A, Brundel BJ, Nattel S. Atrial fibrillation: basic mechanisms, remodeling and triggers. J Interv Card Electrophysiol 2005;13:181-93. (Pubitemid 41372065)
4. Liu T, Li L, Korantzopoulos P, Liu E, Li G. Statin use and development of atrial fibrillation: a systematic review and meta-analysis of randomized clinical trials and observational studies. Int J Cardiol 2008;126:160-70. (Pubitemid 351602110)
5. Liu T, Li GP. Anti-inflammatory effects of long-chain ω3 fatty acids: potential benefits for atrial fibrillation. Med Hypotheses 2005;65:200-1. (Pubitemid 40704560)
6. Liu T, Korantzopoulos P, Li G, Li J. The potential role of thiazolidinediones in atrial fibrillation. Int J Cardiol 2008;128:129-30. (Pubitemid 351905768)
7. Li G, Liu T. The therapeutic strategies of enhancing adiponectin and lowering leptin may be benefit to controlling atrial fibrillation. Med Hypotheses 2009;73:122.
8. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995;92:1954-68.
9. Li GP, Liu T, Liu E. Cardiac electrical stunning is a common feature of cardiac arrhythmias. Med Hypotheses 2006;67:865-7. (Pubitemid 44062131)
10. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612-7. (Pubitemid 30350640)
11. Goette A, Staack T, Röcken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-77. (Pubitemid 30307515)
12. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-80. (Pubitemid 29362407)
13. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005;45:712-9. (Pubitemid 40282586)
14. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005;45:1832-9. (Pubitemid 40789940)
15. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002;417:822-8. (Pubitemid 34670323)
16. Tallant EA, Ferrario CM, Gallagher PE. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the Mas receptor. Am J Physiol Heart Circ Physiol 2005;289:H1560-6.
17. Iwata M, Cowling RT, Gurantz D, et al. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. Am J Physiol Heart Circ Physiol 2005;289:H2356-63.
18. Grobe JL, Mecca AP, Lingis M, et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol 2007;292:H736-42.
19. SantiagoNM, Guimarães PS, Sirvente RA, et al. Lifetime overproduction of circulating Angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling. Hypertension 2010;55:889-96.
20. De Mello WC. Angiotensin (1-7) re-establishes impulse conduction in cardiac muscle during ischaemia-reperfusion. The role of the sodium pump. J Renin Angiotensin Aldosterone Syst 2004;5:203-8.
21. De Mello WC. Angiotensin (1-7) reduces the cell volume of swollen cardiac cells and decreases the swelling-dependent chloride current. Implications for cardiac arrhythmias and myocardial ischemia. Peptides 2010 Dec;31(12):2322-4.
22. Pan CH, Lin JL, Lai LP, Chen CL, Stephen Huang SK, Lin CS. Downregulation of angiotensin converting enzyme II is associated with pacing-induced sustained atrial fibrillation. FEBS Lett 2007;581:526-34. (Pubitemid 46149629)
23. Liu E, Yang S, Xu Z, Li J, Yang W, Li G. Angiotensin-(1-7) prevents atrial fibrosis and atrial fibrillation in long-term atrial tachycardia dogs. Regul Pept 2010;162:73-8.
24. Liu E, Xu Z, Li J, Yang S, Yang W, Li G. Enalapril, irbesartan, and angiotensin-(1-7) prevent atrial tachycardia-induced ionic remodeling. Int J Cardiol 2011;146:364-70.
25. Lin CS, Pan CH, Wen CH, Yang TH, Kuan TC. Regulation of angiotensin converting enzyme II by angiotensin peptides in human cardiofibroblasts. Peptides 2010;31:1334-40.
26. Shewan LG, Coats AJ. Ethics in the authorship and publishing of scientific articles. Int J Cardiol 2010;144:1-2.